Loading
Life sciences · Journal article
Scientific Reports · September 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
We investigated the association of post-therapy serum 131 I counts with treatment outcomes in differentiated thyroid cancer. We prospectively enrolled patients receiving high-activity 131 I as initial postoperative radioactive iodine (RAI) therapy (n = 84), repeat therapy (n = 24), or metastatic disease treatment (n = 23). Serum 131 I counts and day-7 whole-body scintigraphy (WBS) were evaluated against treatment success and recurrence in the non-metastatic cohort, and favorable response (≥ 25% TSH-suppressed thyroglobulin [on-Tg] reduction) and progressive disease in the metastatic cohort. In non-metastatic patients, serum 131 I counts strongly correlated with WBS neck counts (ρ = 0.778, p < 0.001), whereas stimulated thyroglobulin (off-Tg) correlated with WBS counts only in treatment-naïve patients (ρ = 0.334, p = 0.001). Treatment success was independently associated with high serum 131 I counts (OR 11.02) and low off-Tg (OR 88.32), and serum 131 I counts further stratified outcomes within off-Tg-defined groups. In metastatic patients, serum 131 I counts were more strongly associated with on-Tg reduction than off-Tg (OR 45.50 vs. 19.27), and low serum 131 I counts were associated with progressive disease. Findings in the metastatic cohort should be considered exploratory given the small sample size and limited number of progression events. Post-therapy serum 131 I counts correlated with WBS uptake and were associated with subsequent treatment outcomes.